UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Harm Reduction With Pharmacotherapy (HaRP)

Phase 2

Completed

Conditions: Alcohol Use Disorder

Interventions: Behavioral: HRC
Drug: XR-NTX
Other: Placebo

First Posted Date: 2013-08-30

Last Posted Date: 2023-05-10

Lead Sponsor: University of Washington

Target Recruit Count: 308

Registration Number: NCT01932801

Locations: 🇺🇸
University of Washington - Harborview Medical Center, Seattle, Washington, United States

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

Not Applicable

Terminated

Conditions: Stage IIIA Breast Cancer
Stage II Breast Cancer
Stage IIIB Breast Cancer
Male Breast Cancer

Interventions: Radiation: fludeoxyglucose F 18
Device: positron emission tomography
Device: dynamic contrast-enhanced magnetic resonance imaging
Other: laboratory biomarker analysis

First Posted Date: 2013-08-29

Last Posted Date: 2023-11-18

Lead Sponsor: University of Washington

Target Recruit Count: 35

Registration Number: NCT01931709

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

Not Applicable

Completed

Conditions: Stage IIIA Breast Cancer
Stage IB Breast Cancer
Stage IIB Breast Cancer
Estrogen Receptor Positive
Stage IA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
HER2/Neu Negative
Male Breast Carcinoma
Stage IIA Breast Cancer

Interventions: Drug: Fluorothymidine F-18
Procedure: Positron Emission Tomography
Other: Laboratory Biomarker Analysis
Drug: Run-in (short pre-surgery course) of endocrine-targeted therapy

First Posted Date: 2013-08-23

Last Posted Date: 2018-05-15

Lead Sponsor: University of Washington

Target Recruit Count: 28

Registration Number: NCT01928186

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Myopia:the Role of Cone Opsin Mutations & Glasses That Control Axial Elongation

Not Applicable

Withdrawn

Conditions: Myopia

Interventions: Other: Spectacles with holographic diffuser and color neutral tint
Other: Spectacles with holographic diffuser and red-blocking tint
Other: Spectacles with color neutral tint
Other: Spectacles with red-blocking tint

First Posted Date: 2013-08-15

Last Posted Date: 2019-08-14

Lead Sponsor: University of Washington

Registration Number: NCT01923675

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

Phase 1

Completed

Conditions: Recurrent Breast Carcinoma
HER2/Neu Positive
Stage IV Breast Cancer

Interventions: Biological: HER-2/neu Intracellular Domain Protein
Other: Laboratory Biomarker Analysis
Biological: Pertuzumab
Other: Placebo
Biological: Polysaccharide-K
Biological: Trastuzumab

First Posted Date: 2013-08-14

Last Posted Date: 2023-04-18

Lead Sponsor: University of Washington

Target Recruit Count: 31

Registration Number: NCT01922921

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer

Phase 2

Completed

Conditions: Recurrent Breast Carcinoma
Stage IV Breast Cancer

Interventions: Drug: Eribulin Mesylate
Other: Laboratory Biomarker Analysis

First Posted Date: 2013-07-25

Last Posted Date: 2020-07-23

Lead Sponsor: University of Washington

Target Recruit Count: 86

Registration Number: NCT01908101

Locations: 🇺🇸
Skagit Valley Hospital, Mount Vernon, Washington, United States
🇺🇸
Olympic Medical Center, Port Angeles, Washington, United States
🇺🇸
Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States

and more 9 locations

Oligonucleotide Ligation Assay (OLA) Resistance Study

Not Applicable

Completed

Conditions: HIV Positive

Interventions: Other: Pre-ART Oligonucleotide Assay (OLA)

First Posted Date: 2013-07-12

Last Posted Date: 2021-11-17

Lead Sponsor: University of Washington

Target Recruit Count: 991

Registration Number: NCT01898754

Locations: 🇰🇪
Coptic Hospital, Nairobi, Kenya

Mobile Phone Messaging to Improve Women's and Children's Health (Mobile WACh) in Kenya

Not Applicable

Completed

Conditions: Maternal Health
Neonatal Health
Family Planning

Interventions: Behavioral: Two-way SMS Dialogue
Behavioral: One-way SMS Messaging

First Posted Date: 2013-07-09

Last Posted Date: 2016-11-09

Lead Sponsor: University of Washington

Target Recruit Count: 300

Registration Number: NCT01894126

Locations: 🇰🇪
Mathare North Health Centre, Nairobi, Kenya

SWIFT Study in the ED

Not Applicable

Conditions: Mild Traumatic Brain Injury

Interventions: Behavioral: SWIFT
Behavioral: SWIFT-Acute

First Posted Date: 2013-07-09

Last Posted Date: 2016-04-27

Lead Sponsor: University of Washington

Target Recruit Count: 80

Registration Number: NCT01893970

Locations: 🇺🇸
UCSF San Francisco General Hospital and Trauma Center, San Francisco, California, United States

Reducing HIV Stigma for African American Women

Not Applicable

Completed

Conditions: HIV

Interventions: Behavioral: Breast Cancer Screening
Behavioral: Unity Workshop

First Posted Date: 2013-07-08

Last Posted Date: 2017-05-08

Lead Sponsor: University of Washington

Target Recruit Count: 240

Registration Number: NCT01893112

Locations: 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
Northwestern University (NU), Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy